Hologic, Inc. (HOLX) Financial Ratios
30 years of historical data (1996–2025) · Healthcare · Medical - Instruments & Supplies
EV/EBITDA
↑
17.39
↑+33% vs avg
5yr avg: 13.10
30Y Low7.3·High57.6
P/FCF
↑
18.44
↑+32% vs avg
5yr avg: 13.96
30Y Low8.2·High36.4
P/B Ratio
↓
3.43
-6% vs avg
5yr avg: 3.63
30Y Low0.4·High6.5
ROE
↓
11.1%
↑-53% vs avg
5yr avg: 23.7%
30Y Low-61%·High54%
Debt/EBITDA
↑
2.59
↑+26% vs avg
5yr avg: 2.05
30Y Low0.0·High27.3
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
HOLX Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Hologic, Inc. trades at 30.5x earnings, 36% above its 5-year average of 22.5x, sitting at the 56th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.1x, the stock trades at a premium of 38%. On a free-cash-flow basis, the stock trades at 18.4x P/FCF, 32% above the 5-year average of 14.0x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $17.0B | $15.3B | $19.4B | $17.3B | $16.4B | $19.2B | $17.6B | $13.6B | $11.3B | $10.5B | $11.1B |
| Enterprise Value | $17.6B | $16.0B | $19.8B | $17.5B | $17.0B | $21.1B | $20.0B | $16.1B | $14.0B | $13.3B | $13.9B |
| P/E Ratio → | 30.53 | 26.99 | 24.54 | 37.92 | 12.58 | 10.24 | 15.79 | — | — | 13.90 | 33.47 |
| P/S Ratio | 4.14 | 3.73 | 4.80 | 4.28 | 3.37 | 3.40 | 4.66 | 4.04 | 3.50 | 3.43 | 3.92 |
| P/B Ratio | 3.43 | 3.03 | 3.77 | 3.44 | 3.36 | 4.54 | 6.50 | 5.97 | 4.64 | 3.76 | 5.19 |
| P/FCF | 18.44 | 16.62 | 16.90 | 19.17 | 8.20 | 8.90 | 23.76 | 25.38 | 17.97 | — | 16.13 |
| P/OCF | 16.05 | 14.47 | 15.06 | 16.43 | 7.70 | 8.23 | 19.62 | 20.94 | 15.38 | 1262.72 | 14.12 |
P/E links to full P/E history page with 30-year chart
HOLX EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Hologic, Inc.'s enterprise value stands at 17.4x EBITDA, 33% above its 5-year average of 13.1x. The Healthcare sector median is 14.2x, placing the stock at a 22% premium on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 3.89 | 4.92 | 4.33 | 3.49 | 3.75 | 5.31 | 4.78 | 4.34 | 4.36 | 4.92 |
| EV / EBITDA | 17.39 | 15.74 | 16.66 | 17.59 | 8.19 | 7.32 | 13.53 | 26.97 | 57.63 | 7.32 | 13.75 |
| EV / EBIT | 24.69 | 22.05 | 20.11 | 22.17 | 10.08 | 8.61 | 17.91 | — | — | 9.63 | 24.44 |
| EV / FCF | — | 17.35 | 17.34 | 19.37 | 8.49 | 9.82 | 27.07 | 30.06 | 22.27 | — | 20.25 |
HOLX Profitability
Margins and return-on-capital ratios measuring operating efficiency
Hologic, Inc. earns an operating margin of 17.4%. ROE of 11.1% is modest. ROIC of 9.4% represents adequate returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 61.0% | 61.0% | 55.3% | 51.4% | 61.6% | 67.4% | 59.0% | 38.8% | 52.7% | 53.0% | 55.2% |
| Operating Margin | 17.4% | 17.4% | 21.9% | 16.6% | 33.7% | 44.0% | 29.3% | 4.0% | -7.4% | 44.8% | 19.4% |
| Net Profit Margin | 13.8% | 13.8% | 19.6% | 11.3% | 26.8% | 33.2% | 29.5% | -1.2% | -3.5% | 24.7% | 11.7% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 11.1% | 11.1% | 15.6% | 9.2% | 28.6% | 54.0% | 44.7% | -1.7% | -4.3% | 30.7% | 15.7% |
| ROA | 6.2% | 6.2% | 8.6% | 5.0% | 14.5% | 23.2% | 16.2% | -0.6% | -1.5% | 9.9% | 4.4% |
| ROIC | 9.4% | 9.4% | 12.2% | 9.4% | 21.1% | 32.8% | 16.7% | 2.0% | -3.3% | 19.4% | 8.1% |
| ROCE | 8.8% | 8.8% | 11.0% | 8.3% | 20.9% | 36.6% | 19.2% | 2.4% | -4.0% | 21.9% | 8.3% |
HOLX Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Hologic, Inc. carries a Debt/EBITDA ratio of 2.6x, which is moderately leveraged (20% below the sector average of 3.2x). Net debt stands at $667M ($2.6B total debt minus $2.0B cash). Interest coverage of 17.0x signals virtually no risk of debt distress — earnings comfortably cover interest obligations.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.52 | 0.52 | 0.52 | 0.58 | 0.60 | 0.75 | 1.16 | 1.36 | 1.38 | 1.21 | 1.58 |
| Debt / EBITDA | 2.59 | 2.59 | 2.23 | 2.93 | 1.41 | 1.09 | 2.13 | 5.21 | 13.87 | 1.86 | 3.33 |
| Net Debt / Equity | — | 0.13 | 0.10 | 0.04 | 0.12 | 0.47 | 0.90 | 1.10 | 1.11 | 1.02 | 1.32 |
| Net Debt / EBITDA | 0.66 | 0.66 | 0.42 | 0.18 | 0.28 | 0.68 | 1.65 | 4.20 | 11.12 | 1.56 | 2.79 |
| Debt / FCF | — | 0.73 | 0.43 | 0.20 | 0.29 | 0.92 | 3.30 | 4.68 | 4.30 | — | 4.11 |
| Interest Coverage | 16.95 | 16.95 | 8.09 | 7.09 | 17.70 | 26.23 | 9.60 | -0.83 | -1.82 | 9.03 | 3.67 |
HOLX Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Hologic, Inc.'s current ratio of 3.75x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 3.06x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has improved from 3.47x to 3.75x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.75 | 3.75 | 3.69 | 3.47 | 4.12 | 2.39 | 1.79 | 1.68 | 1.23 | 0.79 | 1.47 |
| Quick Ratio | 3.06 | 3.06 | 3.03 | 2.95 | 3.45 | 2.01 | 1.47 | 1.26 | 0.95 | 0.61 | 1.17 |
| Cash Ratio | 2.25 | 2.25 | 2.25 | 2.26 | 2.49 | 0.88 | 0.57 | 0.56 | 0.48 | 0.29 | 0.61 |
| Asset Turnover | — | 0.45 | 0.44 | 0.44 | 0.54 | 0.63 | 0.52 | 0.51 | 0.45 | 0.38 | 0.39 |
| Inventory Turnover | 2.35 | 2.35 | 2.65 | 3.17 | 2.99 | 3.66 | 3.92 | 4.63 | 3.96 | 4.34 | 4.62 |
| Days Sales Outstanding | — | 53.48 | 54.37 | 56.66 | 46.36 | 61.09 | 99.45 | 70.32 | 65.70 | 63.66 | 57.60 |
HOLX Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Hologic, Inc. returns 4.4% to shareholders annually primarily through share buybacks. The earnings yield of 3.3% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 3.3% | 3.7% | 4.1% | 2.6% | 8.0% | 9.8% | 6.3% | — | — | 7.2% | 3.0% |
| FCF Yield | 5.4% | 6.0% | 5.9% | 5.2% | 12.2% | 11.2% | 4.2% | 3.9% | 5.6% | — | 6.2% |
| Buyback Yield | 4.4% | 4.9% | 4.3% | 2.9% | 3.3% | 2.4% | 3.7% | 1.5% | 2.4% | 1.9% | 2.2% |
| Total Shareholder Yield | 4.4% | 4.9% | 4.3% | 2.9% | 3.3% | 2.4% | 3.7% | 1.5% | 2.4% | 1.9% | 2.2% |
| Shares Outstanding | — | $228M | $238M | $249M | $254M | $260M | $265M | $269M | $275M | $286M | $286M |
Peer Comparison
Compare HOLX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 HOLXYou | $17B | 30.5 | 17.4 | 18.4 | 61.0% | 17.4% | 11.1% | 9.4% | 2.6 |
 BDX | $51B | 24.1 | 13.8 | 19.1 | 45.4% | 11.8% | 6.5% | 4.3% | 3.8 |
 BAX | $10B | -11.2 | 27.0 | 31.4 | 30.1% | -2.7% | -14.6% | -1.4% | 14.9 |
 IDXX | $43B | 41.7 | 30.2 | 41.1 | 61.8% | 31.6% | 66.2% | 42.5% | 0.7 |
 DXCM | $27B | 33.0 | 23.3 | 24.7 | 60.0% | 19.6% | 34.5% | 18.7% | 1.2 |
 ISRG | $143B | 51.2 | 38.7 | 57.5 | 66.0% | 29.3% | 16.6% | 15.0% | 0.1 |
 MASI | $9B | -64.3 | 28.0 | 47.6 | 61.9% | 20.5% | -17.1% | 16.5% | 1.6 |
 GH | $17B | -38.8 | — | — | 64.5% | -44.4% | — | -34.9% | — |
 EXAS | $20B | -95.4 | — | 56.1 | 69.7% | -6.4% | -8.7% | -3.6% | — |
 QGEN | $7B | 17.8 | 11.6 | 16.5 | 61.8% | 24.9% | 11.6% | 8.6% | 2.3 |
 NEOG | $2B | -1.8 | 20.2 | — | 47.1% | 1.1% | -41.9% | 0.2% | 6.8 |
| Healthcare Median | — | 22.1 | 14.2 | 18.4 | 63.9% | -4.4% | -33.2% | -11.7% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 30 years · Updated daily
Consensus-Based Analysis Tools
Full Stock Analysis
Deep dive into HOLX consensus models and risk factors.
View Analysis
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
HOLX — Frequently Asked Questions
Quick answers to the most common questions about buying HOLX stock.
What is Hologic, Inc.'s P/E ratio?
Hologic, Inc.'s current P/E ratio is 30.5x. The historical average is 35.9x. This places it at the 56th percentile of its historical range.
What is Hologic, Inc.'s EV/EBITDA?
Hologic, Inc.'s current EV/EBITDA is 17.4x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 21.5x.
What is Hologic, Inc.'s ROE?
Hologic, Inc.'s return on equity (ROE) is 11.1%. The historical average is 4.7%.
Is HOLX stock overvalued?
Based on historical data, Hologic, Inc. is trading at a P/E of 30.5x. This is at the 56th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Hologic, Inc.'s profit margins?
Hologic, Inc. has 61.0% gross margin and 17.4% operating margin. Operating margin between 10-20% is typical for established companies.
How much debt does Hologic, Inc. have?
Hologic, Inc.'s Debt/EBITDA ratio is 2.6x, indicating moderate leverage. A ratio between 2-4x is manageable but warrants monitoring.